J Hort1, A Bartos, T Pirttilä, P Scheltens. 1. Department of Neurology, Memory Disorders Clinic, Charles University in Prague, Second Faculty of Medicinel, University Hospital Motol, Prague, Czech Republic. jakub.hort@seznam.cz
Abstract
BACKGROUND AND PURPOSE: Cerebrospinal fluid (CSF) biomarkers have been reported to be useful in dementia diagnosis. Not much is known about their use in clinical practice in Europe. METHODS: We analyzed data from a survey on the use of CSF biomarkers in the diagnosis of dementia across Europe using a questionnaire which was filled out by representatives of the 25 member countries of the European Federation of Neurological Societies (EFNS). RESULTS: Cerebrospinal fluid beta-amyloid, total tau, and phosphorylated tau proteins are frequently evaluated in the majority of the countries (in 18 out of 23 countries). No major technical or ethical issues were found that would hamper the procedure's ability to become routine in early and differential diagnostics of Alzheimer's disease. Cut-off values for beta-amyloid (median 500, range 300-849 pg/ml), total tau (367; 195-450 pg/ml) and phosphorylated tau (60; 40-85 pg/ml) varied considerably amongst countries and even within every country. CONCLUSIONS: Cerebrospinal fluid analysis of beta-amyloid, tau, and phosphorylated tau is frequently used in Europe. However, the use of various cut off values seriously hampers comparability and yields a potential threat to an interpretation and balanced use in clinical practice. We recommend that each laboratory establishes normative data and that multi-centered studies should be organized to explore the reasons for any differences.
BACKGROUND AND PURPOSE: Cerebrospinal fluid (CSF) biomarkers have been reported to be useful in dementia diagnosis. Not much is known about their use in clinical practice in Europe. METHODS: We analyzed data from a survey on the use of CSF biomarkers in the diagnosis of dementia across Europe using a questionnaire which was filled out by representatives of the 25 member countries of the European Federation of Neurological Societies (EFNS). RESULTS: Cerebrospinal fluid beta-amyloid, total tau, and phosphorylated tau proteins are frequently evaluated in the majority of the countries (in 18 out of 23 countries). No major technical or ethical issues were found that would hamper the procedure's ability to become routine in early and differential diagnostics of Alzheimer's disease. Cut-off values for beta-amyloid (median 500, range 300-849 pg/ml), total tau (367; 195-450 pg/ml) and phosphorylated tau (60; 40-85 pg/ml) varied considerably amongst countries and even within every country. CONCLUSIONS: Cerebrospinal fluid analysis of beta-amyloid, tau, and phosphorylated tau is frequently used in Europe. However, the use of various cut off values seriously hampers comparability and yields a potential threat to an interpretation and balanced use in clinical practice. We recommend that each laboratory establishes normative data and that multi-centered studies should be organized to explore the reasons for any differences.
Authors: Kelvin Y Liang; Mark A Mintun; Anne M Fagan; Alison M Goate; Julie M Bugg; David M Holtzman; John C Morris; Denise Head Journal: Ann Neurol Date: 2010-09 Impact factor: 10.422
Authors: Catherine Pan; Ané Korff; Douglas Galasko; Carmen Ginghina; Elaine Peskind; Ge Li; Joseph Quinn; Thomas J Montine; Kevin Cain; Min Shi; Jing Zhang Journal: J Alzheimers Dis Date: 2015 Impact factor: 4.472
Authors: J A Monge-Argilés; C Muñoz-Ruiz; A Pampliega-Pérez; M J Gómez-López; J Sánchez-Payá; E Rodríguez Borja; M Ruiz-Vegara; F J Montoya-Gutiérrez; C Leiva-Santana Journal: Neurochem Res Date: 2011-03-12 Impact factor: 3.996
Authors: A Leuzy; N J Ashton; N Mattsson-Carlgren; A Dodich; M Boccardi; J Corre; A Drzezga; A Nordberg; R Ossenkoppele; H Zetterberg; K Blennow; G B Frisoni; V Garibotto; O Hansson Journal: Eur J Nucl Med Mol Imaging Date: 2021-03-05 Impact factor: 9.236